Language：Japanese   Publisher：(一社)日本口腔診断学会  

症例は30歳代女性で、かかりつけ歯科医院で撮影したパノラマエックス線写真で上顎右側第三大臼歯部の透過像を指摘され、精査加療目的に当科紹介受診となった。局所麻酔下に生検を施行し歯原性嚢胞の診断を得て、全身麻酔下に右側上顎骨嚢胞摘出術を施行した。上顎右側第二大臼歯近心頬側に縦切開を加え、上顎右側第二大臼歯頬側歯頸部切開、遠心切開と連続させ粘膜骨膜弁を形成した。周囲の骨を削除したところ、上顎右側第三大臼歯を取り囲む嚢胞性病変が確認でき、上顎右側第三大臼歯を抜歯後、嚢胞を摘出した。病理組織学的診断では正角化性歯原性嚢胞であった。現在、術後約5ヵ月が経過しているが再発を示唆する所見は認められず経過良好である。

researchmap

Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

We report a rare case of schwannoma arising from the sublingual glandular branch of the lingual nerve radiologically masquerading as sublingual gland tumor. A 42-year-old female was referred to our department with a painless swelling in the left submandibular region. Contrast-enhanced computed tomography showed a well-circumscribed, heterogeneous low-density tumor with cystic change in the left sublingual region. Magnetic resonance imaging showed a well-circumscribed, heterogeneous sublingual tumor with low-signal intensity on T1-weighted image and high-signal intensity in T2-weighted image. The lesion was diagnosed radiologically as benign sublingual gland tumor. The patient underwent resection of sublingual gland tumor under general anesthesia. There was no definitive continuity between the tumor and the sublingual gland, and the tumor originated from sublingual glandular branch of the lingual nerve. Pathological examination of the specimen showed schwannoma with highly cellular areas (Antoni A) and hypocellular areas (Antoni B). The postoperative course was uneventful without lingual nerve palsy, and there was no recurrence 4 years after surgery.

DOI： 10.1007/s11282-020-00447-w

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: We compared outcomes and toxicities between concurrent retrograde super-selective intra-arterial chemoradiotherapy (IACRT) and concurrent systemic chemoradiotherapy (SCRT) for gingival carcinoma (GC). METHODS: We included 84 consecutive patients who were treated for non-metastatic GC ≥ stage III, from 2006 to 2018, in this retrospective analysis (IACRT group: n = 66; SCRT group: n = 18). RESULTS: The median follow-up time was 24 (range: 1-124) months. The median prescribed dose was 60 (6-70.2) Gy (IACRT: 60 Gy; SCRT: 69 Gy). There were significant differences between the two groups in terms of 3-year overall survival (OS; IACRT: 78.8, 95% confidence interval [CI]: 66.0-87.6; SCRT: 50.4, 95% CI: 27.6-73.0; P = 0.039), progression-free survival (PFS; IACRT: 75.6, 95% CI: 62.7-85.2; SCRT: 42.0, 95% CI: 17.7-70.9; P = 0.028) and local control rates (LC; IACRT: 77.2, 95% CI: 64.2-86.4; SCRT: 42.0, 95% CI: 17.7-70.9; P = 0.015). In univariate analysis, age ≥ 65 years, decreased performance status (PS) and SCRT were significantly associated with worse outcomes (P < 0.05). In multivariate analysis, age ≥ 65 years, clinical stage IV, and SCRT were significantly correlated with a poor OS rate (P < 0.05). Patients with poorer PS had a significantly worse PFS rate. Regarding acute toxicity, 22 IACRT patients had grade 4 lymphopenia, and osteoradionecrosis was the most common late toxicity in both groups. CONCLUSIONS: This is the first report to compare outcomes from IACRT and SCRT among patients with GC. ALL therapy related toxicities were manageable. IACRT is an effective and safe treatment for GC.

DOI： 10.1186/s12885-020-07638-y

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：ELSEVIER SCIENCE INC  

Objective: Intra-oral minor salivary gland tumors are relatively rare. This study aimed to clarify the frequency and distribution of infra-oral minor salivary gland tumors in Japanese patients.Methods: We retrospectively analyzed the histopathological records of 131 patients with minor salivary gland tumors that were surgically treated between 1967 and 2017 at a single institution.Results: Of the 131 minor salivary gland tumors, 61 (47%) were benign and 70 (53%) were malignant. The male:female ratio was 1:1.8 for benign cases and 1:1 for malignant cases. Most of the tumors occurred in the palate, followed by the floor of the mouth. The most frequent minor salivary gland tumor was pleomorphic adenoma among benign tumors and adenoid cystic carcinoma among malignant tumors. The rarest minor salivary gland tumors were Warthin tumors and basal cell adenocarcinoma, accounting for only 0.8% of all cases.Conclusions: The present study determined the incidence rates of these rare tumors.

DOI： 10.1016/j.ajoms.2019.06.007

Web of Science

researchmap

Language：Japanese   Publisher：(一社)日本ハイパーサーミア学会  

researchmap

Language：Japanese   Publisher：(一社)日本ハイパーサーミア学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The aim of this study was to evaluate the prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma (SCC) treated with intra-arterial infusion chemotherapy concurrent with radiotherapy. METHODS: A total of 46 patients were reviewed retrospectively in this study. The treatment schedule comprised intra-arterial chemotherapy (total, 60 mg/m2 docetaxel and 150 mg/m2 cisplatin) and three-dimensional computed tomography based, daily conventional radiotherapy (total, 60 Gy/30 fr) for 6 weeks. RESULTS: The median follow-up period was 40 months (range, 3-110 months). The 3-year overall survival and locoregional control rates for all patients were 64.3% and 84.3%, respectively. The OS rate of the patients with N0-1 was significantly higher than that of the patients with N ≥ 2 (P < .05). No grade 5 toxicities were observed. CONCLUSIONS: Intra-arterial infusion chemotherapy concurrent with radiotherapy was effective for advanced maxillary gingival SCC.

DOI： 10.1002/hed.25607

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

researchmap

Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

AIM: We aimed to retrospectively investigate the outcomes and pathological effects of retrograde superselective intra-arterial chemoradiotherapy (IACRT) combined with hyperthermia on metastatic lymph nodes of patients with oral squamous cell carcinoma. PATIENTS AND METHODS: Patients with lymph node metastasis from oral cancer were treated with IACRT using cisplatin plus docetaxel combined with hyperthermia prior to surgical removal 8 weeks after completion of IACRT and hyperthermia. The locoregional control and overall survival rates were calculated using the Kaplan-Meier method. RESULTS: A total of 35 patients received the combination therapy of whom 26 received it as definitive treatment and in the rest, it was administered as preoperative treatment. The 5-year locoregional control and overall survivaI rates were 95.6% and 80.2% in the definitive-treatment group, and 100% and 66.6% in the preoperative-treatment group, respectively. CONCLUSION: The combination therapy provided good outcomes in patients with lymph node metastases from advanced oral cancer.

DOI： 10.21873/anticanres.13250

PubMed

researchmap

Language：English  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

We herein report a case of squamous cell carcinoma of the buccal mucosa with N3 cervical lymph node metastasis in a 63-year-old man. The patient was treated with combination therapy comprising radiotherapy (2 Gy/day, total of 70 Gy), superselective intra-arterial chemotherapy via a superficial temporal artery (docetaxel, total of 70 mg/m2 and cisplatin, total of 175 mg/m2), cetuximab (initial dose of 400 mg/m2 with subsequent weekly doses of 250 mg/m2 intravenously), and four sessions of hyperthermia for cervical lymph node metastases. The patient responded well to the therapy, with a complete response of the primary tumor. Radical neck dissection was performed with reconstructive surgery, including resection of the overlying skin. A pathologic complete response was achieved for the N3 and all other cervical lymph node metastases. The patient showed no evidence of recurrence in the 3 years following treatment. Based on the findings in the present case, the use of retrograde superselective intra-arterial chemoradiotherapy combined with hyperthermia and cetuximab seems to be a promising modality for patients with N3 cervical lymph node metastasis of oral cancer.

DOI： 10.1007/s11282-018-0319-y

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

researchmap

Publishing type：Research paper (scientific journal)   Publisher：Japan Society for Oral Tumors  

DOI： 10.5843/jsot.31.97

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVES: To evaluate the therapeutic results and rate of organ preservation in patients with squamous cell carcinoma of the tongue treated with retrograde superselective intra-arterial chemoradiotherapy. MATERIALS AND METHODS: Between June 2006 and June 2015, 118 patients with tongue cancer were treated with intra-arterial chemoradiotherapy. Treatment consisted of radiotherapy (total 50-70 Gy) and daily concurrent intra-arterial chemotherapy (docetaxel, total 50-70 mg/m2; cisplatin, total 125-175 mg/m2) for 5-7 weeks. Locoregional control and overall survival rates were calculated by the Kaplan-Meier method. Cox's proportional hazards model was used for both univariate and multivariate analyses. RESULTS: The median follow-up for all patients was 38.5 months (range, 3-129 months). After intra-arterial chemoradiotherapy, primary site complete response was achieved in 113 (95.8%) of 118 cases. Three-year locoregional control and overall survival rates were 80.3% and 81.5%, respectively. Grade 3 or 4 toxicities included neutropenia in 16.1% and mucositis in 87.3%. Grade 3 toxicities included anemia in 12.7%, thrombocytopenia in 3.4%, nausea/vomiting in 3.4%, dermatitis in 45.7%, dysphagia in 74.6%, and fever in 2.5% of patients. Late toxicity consisting of grade 3 osteoradionecrosis of the jaw occurred in 4.2% of patients. On univariate analysis, T stage and overall stage were significantly associated with locoregional control, and N stage and overall stage were significantly associated with overall survival. On multivariate analysis, the only significant predictor of overall survival was overall stage classification. CONCLUSION: Retrograde superselective intra-arterial chemoradiotherapy for tongue cancer provided good overall survival and locoregional control.

DOI： 10.1016/j.oraloncology.2018.02.002

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Obstructive sialadenitis of the submandibular gland is commonly caused by sialoliths, but more rarely by foreign body-induced sialoliths. Here, we report minimally invasive sialendoscopic removal of fish bone-induced sialoliths in the duct of the submandibular gland. A 43-year-old woman presented with recurrent swelling of the right submandibular gland at other hospital. Computed tomography (CT) showed an 8-mm linear calcification in the posterior part of Wharton's duct. The lesion was deemed difficult to remove and she was followed up. However, because the lesion did not resolve spontaneously within 9 months and chronic sialadenitis symptoms persisted, she was referred to our department for endoscopic removal. CT showed a linear calcification (5.6×1.2×0.8mm) connecting 2 spherical calcifications (2.3×2.1×1.9mm; 1.8×1.4×1.1mm) in the anterior part of Wharton's duct. The patient underwent endoscopic removal of the lesion using a 1.6-mm-diameter sialendoscope under local anesthesia. The specimen contained a fish bone connecting 2 sialoliths. The patient was unaware of the fish-bone injury. After removal, there was no recurrence of submandibular gland swelling during 6 months follow-up.

DOI： 10.1016/j.anl.2017.03.010

PubMed

researchmap

Language：English  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Elsevier Ltd  

Objective As the first step in sialendoscopy, the orifice of the salivary duct is progressively dilated using different sized salivary probes before the sialendoscope is inserted. However, the procedure can be challenging as surgeons may lose the duct orifice and find it difficult to re-identify after each probe change. To overcome this problem, we previously reported a simple technique using a guidewire, but a more cost-effective and time-saving approach is needed. We describe a modified method for simple dilatation of the papilla orifice to introduce the sialendoscope easily into the ductal lumen. Methods A 24 G angiocatheter and a 0.5-mm-diameter salivary or lacrimal probe is prepared preoperatively. The tip of the angiocatheter (3.3–0.7 mm outer diameter) is cut and the probe is threaded into the tapered catheter. On identifying the duct orifice by pressing the salivary gland, they are inserted together into the duct orifice. Only the catheter is advanced into the duct along the probe to dilate the orifice. The orifice can be easily dilated without losing the papilla entrance. After removing the catheter, a sialoendoscope can be inserted easily into the duct. Results We performed more than 100 procedures using this modified method and the sialendoscope could be inserted into the duct within 10 s after probe insertion into the orifice. Conclusion This method offers simple dilatation of the papilla orifice to introduce the sialendoscope.

DOI： 10.1016/j.ajoms.2017.05.003

Scopus

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：SPRINGER  

Aneurysms of the external carotid artery and its branches are rare, and usually occur in the more superficial branches. Lingual artery (LA) aneurysms are particularly rare, and pseudoaneurysms are associated with trauma, infection, and surgical intervention. Only a few cases of idiopathic LA aneurysms have been reported in the English literature. LA aneurysms can be fatal if they are not recognized and treated. Here, we report a case of bilateral idiopathic aneurysms of the LA identified by three-dimensional (3D) computed tomography angiography (CTA). An 80-year-old man with right tongue cancer (T2N0M0) and left tongue leukoplakia was referred to our department for treatment. He had no previous history of trauma, infection, surgery, or aneurysm in the oral and maxillofacial region. CTA with 3D reconstruction showed right and left aneurysms of the LA, with sizes of 2.4 x 2.3 x 2.1 mm and 3.4 x 3.2 x 2.5 mm, respectively. The patient underwent bilateral partial glossectomy under general anesthesia without intervention for the aneurysms, and the post-operative course was uneventful. A radiological follow-up has been performed regularly for the small unruptured aneurysms.

DOI： 10.1007/s11282-016-0255-7

Web of Science

researchmap

Language：Japanese   Publisher：(一社)日本ハイパーサーミア学会  

researchmap

Language：Japanese   Publisher：(NPO)日本口腔科学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：ELSEVIER SCIENCE INC  

Objective. To evaluate the therapeutic results and control of occult neck metastasis in patients with T2-4N0 oral tongue squamous cell carcinoma treated with retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy.
Study Design. Forty-two patients with T2-4N0 tongue cancer (17 with late T2; 13 with T3; and 12 with T4a disease, M0) were treated with intra-arterial chemoradiotherapy. Treatment consisted of retrograde superselective intra-arterial chemotherapy (docetaxel 50-70 mg/m(2), cisplatin 125-175 mg/m(2)) and daily concurrent radiotherapy (50-70 Gy) for 5-7 weeks.
Results. The median follow-up for all patients was 46.5 months (range, 8-105 months). Primary-site complete response was achieved in 42 of 42 cases (100%). Three-year overall survival, progression-free survival, and local control rates were 85.0%, 77.8%, and 91.7%, respectively. Delayed neck metastasis was detected in 5 of 42 cases (11.9%). Grade 3 or 4 toxic changes included oral mucositis in 92.9%, neutropenia in 21.4%, and thrombocytopenia in 4.8%. Grade 3 toxicities included anemia in 16.7%, radiation dermatitis in 9.5%, nausea in 4.8%, and fever in 2.4%.
Conclusions. Retrograde superselective intra-arterial chemotherapy for T2-4N0 tongue cancer provided good overall survival and local control rates and was effective for occult neck metastasis.

DOI： 10.1016/j.oooo.2017.02.004

Web of Science

researchmap

Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

researchmap

Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

researchmap

Language：Japanese   Publisher：(公社)日本医学放射線学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/ajco.12502

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：CIG MEDIA GROUP, LP  

Background: The efficacy, toxicity, and prognostic factors of high-dose proton beam therapy (PBT) for peripheral stage I non-small-cell lung cancer were assessed in this retrospective study. Materials and Methods: Fifty patients with peripheral stage I non-small-cell lung cancer, two of whom had heterochronic multiple lung cancers, underwent high-dose PBT between January 2009 and September 2014. The relative biological effectiveness of the proton beam was defined as 1.1. The beam energy and spread-out Bragg peak were fine-tuned for the 90% isodose volume of the prescribed dosage to encompass the planning target volume. The cumulative survival curves were calculated using the Kaplan-Meier method. Treatment toxicities were evaluated using version 4 of the Common Terminology Criteria for Adverse Events, version 4. Results: The study included 35 males and 15 females with a median age of 72.5 years. The median follow-up period was 22.8 months. The clinical stage was IA in 44 (85%) and IB in eight (15%) tumors. The total dose of PBT was 66 GyE in 10 fractions in all tumors. Three-year overall survival rate among all patients was 87.9% (95% confidence interval [CI], 94.8%-73.2%). Forty-five patients were alive, and 5 were dead. Three-year local control and progression-free survival rates were 95.7% (95% CI, 98.9%-83.8%) and 76.3% (95% CI, 86.9%-59.3%), respectively. Only one patient experienced Grade 2 pneumonitis. Conclusion: High-dose PBT may be an effective and safe treatment option for patients with stage I non-small-cell lung cancer. (C) 2015 Elsevier Inc. All rights reserved.

DOI： 10.1016/j.cllc.2015.11.013

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：WILEY  

BackgroundThe purpose of this study was to evaluate the efficacy and toxicities of proton beam therapy combined with intra-arterial infusion chemotherapy via superficial temporal and occipital arteries for recurrent oral cavity squamous cell carcinoma (SCC).
MethodsBetween October 2009 and June 2013, 46 patients with recurrent oral cavity SCC were treated by proton beam therapy combined with intra-arterial infusion chemotherapy of cisplatin (CDDP) and docetaxel. Treatment consisted of proton beam therapy (28.6-74.8 GyE in 13-34 fractions) and intra-arterial infusion chemotherapy (CDDP, 30-50 mg/body/week; docetaxel, 5-25 mg/body/week).
ResultsOne-year and 2-year overall survival (OS) rates were 65% and 46%, respectively. One-year and 2-year local control rates were 81% and 70%, respectively.
ConclusionThese findings suggest that proton beam therapy combined with intra-arterial infusion chemotherapy could be applied effectively and safely for patients with recurrent oral cavity SCC. (c) 2016 Wiley Periodicals, Inc. Head Neck 38:1145-1151, 2016

DOI： 10.1002/hed.24421

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer India  

The aim of this study was to evaluate the efficacy and safety of proton beam therapy for patients with locally recurrent parotid cancer. Between 2009 and 2012, ten patients with locally recurrent parotid gland cancer were treated with proton beam therapy (70.2 Gy equivalents in 32 fractions) with or without intra-arterial infusion chemotherapy of cisplatin (50 mg/body/week, for a total of 5–8 weeks). The median follow-up was 24 months (range 10–49 months). The 1-year overall survival and local control rates were 80 %, and the 3-year overall survival and local control rates were 60 %. None of the patients experienced grade 3–5 toxicities in the treatment or the follow-up periods. These findings suggest that proton beam therapy could be applied effectively and safely for patients with locally recurrent parotid gland cancer.

DOI： 10.1007/s12070-016-1008-y

Scopus

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：BIOMED CENTRAL LTD  

Background: The purpose of this study is to retrospectively evaluate the incidence of lung toxicities after proton beam therapy (PBT) in patients with idiopathic pulmonary fibrosis (IPF).
Methods: Patients diagnosed with primary lung cancer or lung metastasis who were treated with PBT between January 2009 and May 2015 were recruited from our database retrospectively. Cases of pneumonitis (excluding infection-related pneumonitis) were evaluated using the Common Terminology Criteria for Adverse Events version 4.0, and the Fletcher-Hugh-Jones classification of respiratory status was used to evaluate pretreatment and posttreatment respiratory function.
Results: Sixteen IPF patients received PBT for lung tumors, 15 received PBT for primary lung cancer, and one patient received PBT for metastasis from lung cancer. The cohort was composed of 14 men and 2 women, with a median age of 76 years (range: 63-89 years). The median follow-up time was 12 months (range: 4-39 months). The median dose of PBT was 80.0 Gy relative biological dose effectiveness (RBE) (range: 66.0-86.4 Gy [RBE]). The cumulative incidence of pneumonitis was 19.8 % (95 % confidence interval [CI]: 0-40.0 %), including one case of grade 5 pneumonitis. Reduced respiratory function was observed after PBT in seven patients, including one patient with pleural dissemination; five of these patients required home oxygen therapy.
Conclusions: This study suggests that PBT can be performed more safely in IPF patients than surgery or X-ray irradiation. Although PBT has become a treatment choice for lung tumors of patients with IPF, the adverse events warrant serious attention.

DOI： 10.1186/s13014-016-0637-3

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: Proton beam therapy (PBT), compared with conventional radiotherapy, can deliver high-dose radiation to a tumor, while minimizing doses delivered to surrounding normal tissues. The better dose distribution of PBT may contribute to the improvement in local control rate and reduction in late adverse events. We evaluated therapeutic results and toxicities of PBT combined with selective intra-arterial infusion chemotherapy (PBT-IACT) in patients with stage III-IVB squamous cell carcinoma of the tongue. MATERIALS AND METHODS: After 2 systemic chemotherapy courses and whole-neck irradiation (36 Gy in 20 fractions), we administered concurrent chemoradiotherapy comprising PBT for the primary tumor [28.6-33 Gy(RBE) in 13-15 fractions] and for the metastatic neck lymph node [33-39.6 Gy(RBE) in 15-18 fractions] with weekly retrograde intra-arterial chemotherapy by continuous infusion of cisplatin with sodium thiosulfate. RESULTS: Between February 2009 and September 2012, 33 patients were enrolled. The median follow-up duration was 43 months. The 3-year overall survival, progression-free survival, local control rate, and regional control rate for the neck were 87.0, 74.1, 86.6, and 83.9 %, respectively. Major acute toxicities >grade 3 included mucositis in 26 cases (79 %), neutropenia in 17 cases (51 %), and dermatitis in 11 cases (33 %). Late grade 2 osteoradionecrosis was observed in 1 case (3 %). CONCLUSIONS: PBT-IACT for stage III-IVB tongue cancer has an acceptable toxicity profile and showed good treatment results. This protocol should be considered as a treatment option for locally advanced tongue cancer.

DOI： 10.1007/s00432-015-2069-0

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：OXFORD UNIV PRESS  

This study aimed to evaluate the efficacy and toxicity of proton beam therapy combined with cisplatin intra-arterial infusion via a superficial temporal artery as treatment for maxillary sinus carcinoma.
Twenty-six patients with confirmed maxillary sinus carcinoma were enrolled in this study from May 2009 to April 2011. Patients underwent proton beam therapy and intra-arterial infusion chemotherapy with cisplatin.
The median total dose was 70.4 GyE per 32 fractions, and the median dose of cisplatin was 300 mg/body for six cycles of intra-arterial infusion. The 3-year overall survival rate was 58% for all patients (n = 26), 58% for patients with stage T4 disease (n = 12), 57% for patients with &lt; Stage T3 disease (n = 14), 66% for patients with squamous cell carcinoma (n = 15) and 45% for patients with non-squamous cell carcinoma (n = 11). Two patients developed non-hematologic side effects such as Grade 3 radiation dermatitis, one developed osteonecrosis and one developed brain necrosis. Ocular/visual problems occurred in three patients, which included Grade 4 retinopathy and Grade 3 cataract in one and two patients, respectively.
Proton beam therapy combined with cisplatin intra-arterial infusion administered via a superficial temporal artery appears to be safe and effective for maxillary sinus carcinoma.

DOI： 10.1093/jjco/hyv160

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：ASSOC RADIOLOGY & ONCOLOGY  

Background. In an aging society, increasing number of older patients are diagnosed with esophageal cancer. The purpose of this study was to assess the clinical efficacy and safety of proton beam therapy for older patients with esophageal cancer.
Patients and methods. Older patients (age: &gt;= 65 years) newly diagnosed with esophageal cancer between January 2009 and June 2013 were enrolled in this study. All patients underwent either proton beam therapy alone or proton beam therapy with initial X-ray irradiation. Toxicities were evaluated using the Common Terminology Criteria for Adverse Events version 4.0.
Results. Twenty patients were eligible for this study and all completed the treatment. The median age was 78 years (range: 65-89 years) and the median follow-up time was 26.5 months (range: 6-62 months). Seven patients had lymph node metastases and 10 had stage II/III cancer. The median dose of proton beam therapy was 72.6 Gy relative biological dose effectiveness (RBE) (range: 66-74.8 Gy [RBE]) for proton beam therapy alone and 33 Gy (RBE) (range: 30.8-39.6 Gy [RBE]; total dose range: 66.8-75.6 Gy [RBE]) for proton beam therapy with initial X-ray irradiation. The 2-year overall survival rate was 81.8% (95% confidence interval [CI]: 62.4%-100%), and the 2-year local control rate was 89.4% (95% CI: 75.5%-100%). Grade 2 or 3 toxicities occurred in some cases; however, no grade 4 or 5 toxicity was observed.
Conclusions. High-dose (66-75.6 Gy [RBE]) proton beam therapy without chemotherapy was an efficacious and safe treatment for older patients with esophageal cancer.

DOI： 10.1515/raon-2015-0034

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：MULTIMED INC  

Background We conducted a preliminary retrospective evaluation of the efficacy and toxicity of proton-beam therapy (PBT) for stage III non-small-cell lung cancer.
Methods Between January 2009 and August 2013, 27 patients (26 men, 1 woman) with stage III non-small-cell lung cancer underwent PBT. The relative biologic effectiveness value of the proton beam was defined as 1.1. The beam energy and spread-out Bragg peak were fine-tuned such that the 90% isodose volume of the prescribed dose encompassed the planning target volume. Of the 27 patients, 11 underwent neoadjuvant chemotherapy. Cumulative survival curves were calculated using the Kaplan-Meier method. Treatment toxicities were evaluated using version 4 of the Common Terminology Criteria for Adverse Events.
Results Median age of the patients was 72 years (range: 57-91 years), and median follow-up was 15.4 months (range: 7.8-36.9 months). Clinical stage was IIIA in 14 patients (52%) and IIIB in 13 (48%). The median dose of PBT was 77 GyE (range: 66-86.4 GyE). The overall survival rate in the cohort was 92.3% at 1 year and 51.1% at 2 years. Locoregional failure occurred in 7 patients, and distant metastasis, in 10. In 2 patients, initial failure was both locoregional and distant. The 1-year and 2-year rates of local control were 68.1% and 36.4% respectively. The 1-year and 2-year rates of progression-free survival were 39.9% and 21.4% respectively. Two patients experienced grade 3 pneumonitis.
Conclusions For patients with stage III non-small-cell lung cancer, PBT can be an effective and safe treatment option.

DOI： 10.3747/co.22.2523

Web of Science

researchmap

Language：English   Publisher：3-4  

DOI： 10.18999/nagjms.66.3-4.129

PubMed

CiNii Books

researchmap

Other Link： http://search.jamas.or.jp/link/ui/2005075124

Language：English   Publishing type：Research paper (scientific journal)   Publisher：PERGAMON-ELSEVIER SCIENCE LTD  

Adenovirus (Ad) vectors are commonly used in gene therapy trials because of their efficiency in gene transfer. However, their use is limited by immune responses that reduce transgene expression and decrease the efficiency of repeated vector administration. In this study, the efficacy of gene transduction and the tumor-cell killing effect on four human oral (SAS, HSC-2, HSC-3, HSC-4) and one murine squamous cell carcinoma cell (SCC-7, a kind gift of Dr. M. Hiraoka, Kyoto University) lines in vitro with Ad vector conjugated with catioic liposome (Ad/SUV) was evaluated. Ad/SUV resulted in two to five-fold over higher transduction efficiency in four human and one murine cell lines in vitro than Ad vector alone. The optimal Ad-SUV ratio was determined as 10(6) pfu of Ad vector with 1 mumol SUV. Ad/SUV showed more tumor-cell killing effect than Ad vector alone. Furthermore, the shielding effects of Ad vector with Ad/SUV from neutralizing antibody were evaluated. We also found that Ad/SUV is less susceptible to inactivation by neutralizing antibodies in vitro. The efficacy of gene transduction with Ad vector was blocked more than 70% with neutralizing serum, while Ad/SUV retained approximately 50% of the control activity in vitro.
On the basis of these results, the anti-tumor effect with suicide gene therapy using Ad/SUV in vivo was evaluated. Three injections of Ad/SUV showed the inhibition of tumor growth compared with control in vivo. Our results suggested that an enhanced anti-tumor effect on human oral squamous cell carcinoma would be obtained with repeated administrations of Ad/SUV. (C) 2003 Elsevier Science Ltd. All rights reserved.

DOI： 10.1016/S1368-8375(03)00047-2

Web of Science

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：OXFORD UNIV PRESS  

Background: Despite an increasing number of patients suffering from squamous cell carcinomas of the tongue, little is known about the molecular mechanisms involved in the origin and development of these neoplasms.
Methods: We screened microdissected tongue squamous cell carcinoma (TSC) specimens from 28 consecutive, previously untreated, Japanese patients for mutations in the p53 tumor-suppressor gene single-strand conformation polymorphism analysis (exons 5, 6, 7, 8) and direct genomic sequencing.
Results: Among them, 24 tumor specimens were well differentiated, three moderately and one poorly differentiated, according to the WHO classification. Mutations in the p53 tumor-suppressor gene were detected in only two out of the 28 (7%) tumor specimens. One was well differentiated and the other was poorly differentiated.
Conclusions: Our results suggest that p53 gene mutations are less frequent in well differentiated TSC. These results indicate that mutations in the p53 gene may not be strongly involved in the development of well differentiated TSC.

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：KARGER  

Objective: The purpose of this study was to evaluate the clinical efficacy, histopathological efficacy, and response to preoperative thermochemoradiotherapy for N-3 cervical lymph node metastases of oral cancer. Methods: Preoperative thermochemoradiotherapy was performed in 8 patients with oral cancer and N-3 cervical lymph node metastasis. These patients underwent four-weekly sessions of hyperthermia, combined with radiotherapy (40 Gy) as well as chemotherapy with cisplatin (CDDP; 100 mg/m(2)), all prior to surgery. Radical neck dissection was performed 4 weeks after completion of preoperative thermochemoradiotherapy. Results: The preoperative treatment of cervical lymph node metastases yielded a partial response in 6 patients, while 2 patients demonstrated no change. Histopathologically, grade III was detected in 1, grade IIb in 4 and grade IIa in 3 patients after surgery, according to the criteria of Shimosato. The follow-up period ranged from 13 to 64 months (mean 34). Of the 8 patients, 2 died (11 of lymph node metastasis and I had metastasis to a distant site), and 6 patients were alive at the last follow-up, with the longest postoperative disease-free survival being 63 months. The 5-year cumulative survival rate was 70.0%. Conclusion: These results indicate that preoperative thermochemoradiotherapy is a promising modality for patients with N-3 cervical lymph node metastasis of oral cancer. Copyright (C) 2002 S. Karger AG, Basel.

DOI： 10.1159/000059571

Web of Science

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：NATURE PUBLISHING GROUP  

A 16-year-old male was evaluated for a 1-month history of alveolar bone resorption, which had been treated with endodontics by a neighborhood dentist. Intraoral examination showed slight gingival swelling and teeth mobility. However, no tumor mass was seen. The panoramic image showed resorption of alveolar bone and loss of teeth lamina dura. Because he complained of general fatigue, he was introduced to the internist, Biopsies of gingiva and bone marrow aspiration revealed a massive proliferation of lymphoblasts expressing CD10, 19, 20 and HLA-DR antigens on the surface. Their karyotypes were abnormal; 46, XY, t (8;14) (q24;q32). Accordingly, he was diagnosed as Burkitt's lymphoma, and received intensive chemotherapy which relieved his symptoms and decreased his tumor. However, his disease soon became refractory to chemotherapy, and he died 11 weeks after the onset.

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：PERGAMON-ELSEVIER SCIENCE LTD  

A case of recurrent ameloblastic fibrosarcoma (AFS) in the mandibular molar region of a 22-year-old male is reported. The tumor was first diagnosed as a sarcoma of undetermined origin, because the benign epithelial component of AFS had disappeared after repeated surgical procedures. The lesion grew rapidly in the time from hospital admission until operation, suggesting progression from low to high malignancy. The correlation between the benign epithelial component and malignancy is discussed. (C) 1999 Elsevier Science Ltd. All rights reserved.

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：PERGAMON-ELSEVIER SCIENCE LTD  

We developed a new technique of superselective intra-arterial chemotherapy for tongue cancer using a modified (1.35 mm) angiographic catheter. The catheter was confirmed to be inserted into the lingual artery by the new technique. We measured the platinum concentrations in resected tumour tissues after infusion of carboplatin (CBDCA) at 20 mg/m(2) over 30 min from 30 min before tumour resection in 12 patients with cancer of the tongue (6 patients: superselective intra-arterial infusion; 6 patients: conventional intra-arterial infusion). The mean platinum concentration in tumour tissue was 10.5 +/- 1.2 mu g/g wet, which was more than twice higher than, and significantly different from, 4.3 +/- 3.8 mu g/g wet by the conventional intra-arterial infusion method. This new superselective intra-arterial infusion method allows direct infusion of the anticancer agent into the artery supplying the tumour and is expected to become a new therapeutic modality for cancer of the tongue. (C) 1998 Elsevier Science Ltd. All rights reserved.

Web of Science

researchmap

Language：English   Publishing type：Research paper (international conference proceedings)   Publisher：MACMILLAN INDIA LTD  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：TAYLOR & FRANCIS LTD  

Eight patients with primary cancer of the oral cavity were preoperatively treated by combined treatment with hyperthermia and chemotherapy. They received two courses of chemotherapy, which included intra-arterial infusion of 100 mg of cisplatin (CDDP) and 25 mg of peplomycin (PEP) via the superficial temporal artery. The patients also received interstitial hyperthermia for 45 min once a week using the Implant Heating System (IHS) with chemotherapy. IHS consists of ferromagnetic implant, induction coil and generator to produce high frequency magnetic field. The ferromagnetic implant is made of Fe-Pt alloy (Fe:73%, Pt:27%), and has a Curie temperature of 68 degrees C. As a result, clinical complete response (CR) was observed in seven patients and partial response (PR) in one, and postoperative pathological examination showed no residual tumour cells in any specimen. Combined interstitial hyperthermia by IHS and chemotherapy is thus found to be an effective therapeutic method for treating oral cancers.

Web of Science

researchmap

Language：Japanese   Publishing type：Rapid communication, short report, research note, etc. (scientific journal)  

researchmap

Language：Japanese   Publisher：(一社)日本口腔腫瘍学会  

頭頸部悪性腫瘍において遠隔転移は最も予後に影響する因子である。今回、われわれは肝門部リンパ節転移と腹膜播種性転移に至った。まれな下顎歯肉癌症例を経験した。患者は69歳、男性。右側下顎歯肉扁平上皮癌(T4aN3M0)に対し超選択的動注化学放射線治療を施行した。治療後1ヵ月でのFDG-PET/CT検査で肝門部リンパ節腫大を認めた。その後、腹水を伴う腹膜播種性転移を認めたため入院したが急速に全身状態が悪化し多臓器不全にて死亡した。病理解剖検査の結果、肝門部リンパ節腫大と腹膜播種性転移はいずれも右側下顎歯肉癌の転移であると診断された。(著者抄録)

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

Language：Japanese   Publisher：(一社)日本口腔診断学会  

症例は70歳代男性で、右側口底部の腫瘤を自覚したが放置していた。その後に腫瘤の増大を認めたため近医歯科を受診した。口底腫瘍と診断され、某総合病院歯科口腔外科を紹介され生検が行われた。扁平上皮癌と診断されたため、加療目的に当科を紹介受診となった。画像所見より正中よりやや右側の口底癌の左側耳下腺リンパ節への転移が疑われたが、腫瘍がT1であり、健側の表在リンパ節であることより、リンパ節内に生じたWarthin腫瘍の可能性も考えられた。そのため、センチネルリンパ節生検を行った。病理組織学的所見では、耳下腺リンパ節は円柱状細胞と立方状細胞の二層性配列を示す上皮が管状、嚢胞状に増生し、間質には濾胞形成を伴うリンパ球浸潤を認め、Warthin腫瘍と診断した。センチネルリンパ節に転移を認めなかったため、経過観察を行い、術後11ヵ月経過するが無病生存中である。

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J02383&link_issn=&doc_id=20181105220004&doc_link_id=10.15214%2Fjsodom.31.211&url=https%3A%2F%2Fdoi.org%2F10.15214%2Fjsodom.31.211&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_2.gif

researchmap

Language：Japanese   Publisher：(一社)日本ハイパーサーミア学会  

researchmap

Language：Japanese  

researchmap

Language：Japanese  

researchmap

researchmap

Language：Japanese  

DOI： 10.15214/jsodom.31.21

researchmap

researchmap

researchmap

researchmap

researchmap

Language：Japanese  

researchmap

Language：Japanese  

researchmap

Language：Japanese  

researchmap

Language：Japanese  

researchmap

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

DOI： 10.5843/jsot.29.172

researchmap

Language：Japanese  

DOI： 10.15214/jsodom.30.193

researchmap

Language：Japanese  

DOI： 10.15214/jsodom.30.223

researchmap

researchmap

DOI： 10.15214/jsodom.30.52

researchmap

researchmap

Language：Japanese  

DOI： 10.5843/jsot.28.65

researchmap

Language：English   Presentation type：Poster presentation  

researchmap

Language：English   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：English   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：English   Presentation type：Poster presentation  

researchmap

Language：English   Presentation type：Poster presentation  

researchmap

researchmap

Language：Japanese   Presentation type：Oral presentation (general)  

researchmap

Language：Japanese  

researchmap

Language：Japanese  

researchmap